Literature DB >> 27394135

Mutational Spectrum of CYP24A1 Gene in a Cohort of Italian Patients with Idiopathic Infantile Hypercalcemia.

Maddalena Gigante1, Luisa Santangelo, Sterpeta Diella, Gianluca Caridi, Lucia Argentiero, Maria Michela D''Alessandro, Marida Martino, Emma Diletta Stea, Gianluigi Ardissino, Vincenza Carbone, Silvana Pepe, Domenico Scrutinio, Silvio Maringhini, Gian Marco Ghiggeri, Giuseppe Grandaliano, Mario Giordano, Loreto Gesualdo.   

Abstract

BACKGROUND/AIMS: Loss-of-function mutations in the CYP24A1 gene, which encodes the vitamin D-24 hydroxylase, have been recognized as a cause of elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrocalcinosis and nephrolithiasis in infants and adults. As only a case report describing 2 adult patients has been reported in Italian population, we report here the mutation analysis of CYP24A1 gene in an Italian cohort of 12 pediatric and adult patients with idiopathic infantile hypercalcemia (IIH).
METHODS: We performed mutational screening of CYP24A1 gene in a cohort of 12 Italian patients: 8 children with nephrocalcinosis, hypercalcemia and PTH levels <10 pg/ml and 4 adult patients with nephrolithiasis, mild hypercalcemia and PTH levels <10 pg/ml from 11 unrelated Italian families. Clinical and biochemical data were collected. Genomic DNA was extracted from peripheral blood leucocytes using standard methods, and whole coding sequence of CYP24A1 gene was analysed in all patients and family members by polymerase chain reaction and direct sequencing. The potential pathogenicity of the newly identified missense mutations was evaluated by 3 different in silico approaches (Sorting Intolerant from Tolerant, Polyphen and Mutation Taster) and by comparative analysis in 14 different species using ClustalW software.
RESULTS: CYP24A1 bi-allelic mutations were found in 8 individuals from 7 Italian families (7/11; 64%). Overall, 6 different CYP24A1 mutations, including one small deletion (p.Glu143del), 4 missense mutations (p.Leu148Pro; p.Arg396Trp; p.Pro503Leu; p.Glu383Gln) and one nonsense mutation (p.Tyr220*) were identified. Two out of 6 mutations (p.Tyr220* and p.Pro503Leu) were not previously described. Moreover, a new CYP24A1 variant was identified by genetic screening of asymptomatic controls.
CONCLUSION: To the best of our knowledge, this is the first report of a CYP24A1 molecular analysis performed in an Italian cohort of adult and pediatric Italian patients. This study (1) confirms that CYP24A1 plays a causal role in some but not all cases of IIH (64%); (2) expands the spectrum of known CYP24A1 pathogenic mutations; (3) describes 2 hotspots detected in 50% of all Italian cases; and (4) emphasizes the importance of recognition and genetic diagnosis of CYP24A1 defects in infantile as well as adult hypercalcemia.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27394135     DOI: 10.1159/000446663

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass.

Authors:  Pietro Manuel Ferraro; Angelo Minucci; Aniello Primiano; Elisa De Paolis; Jacopo Gervasoni; Silvia Persichilli; Alessandro Naticchia; Ettore Capoluongo; Giovanni Gambaro
Journal:  Urolithiasis       Date:  2016-09-17       Impact factor: 3.436

2.  Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations.

Authors:  Marguerite Hureaux; Arnaud Molin; Nadine Jay; Anne Hélène Saliou; Emmanuel Spaggiari; Rémi Salomon; Alexandra Benachi; Rosa Vargas-Poussou; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2018-06-29       Impact factor: 3.714

Review 3.  Tubular and genetic disorders associated with kidney stones.

Authors:  Nilufar Mohebbi; Pietro Manuel Ferraro; Giovanni Gambaro; Robert Unwin
Journal:  Urolithiasis       Date:  2016-11-28       Impact factor: 3.436

4.  CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.

Authors:  Colin Patrick Hawkes; Dong Li; Hakon Hakonarson; Kevin E Meyers; Kenneth E Thummel; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

5.  Duplex high resolution melting analysis (dHRMA) to detect two hot spot CYP24A1 pathogenic variants (PVs) associated to idiopathic infantile hypercalcemia (IIH).

Authors:  Maria De Bonis; Elisa De Paolis; Maria Elisabetta Onori; Giorgia Mazzuccato; Antonio Gatto; Pietro Ferrara; Pietro Manuel Ferraro; Andrea Urbani; Angelo Minucci
Journal:  Mol Biol Rep       Date:  2021-04-17       Impact factor: 2.316

6.  Vitamin D and Diseases of Mineral Homeostasis: A Cyp24a1 R396W Humanized Preclinical Model of Infantile Hypercalcemia Type 1.

Authors:  René St-Arnaud; Alice Arabian; Dila Kavame; Martin Kaufmann; Glenville Jones
Journal:  Nutrients       Date:  2022-08-06       Impact factor: 6.706

7.  Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations.

Authors:  Agnieszka Janiec; Paulina Halat-Wolska; Łukasz Obrycki; Elżbieta Ciara; Marek Wójcik; Paweł Płudowski; Aldona Wierzbicka; Ewa Kowalska; Janusz B Książyk; Zbigniew Kułaga; Ewa Pronicka; Mieczysław Litwin
Journal:  Nephrol Dial Transplant       Date:  2021-07-23       Impact factor: 5.992

8.  24-Hydroxylase Deficiency Due to CYP24A1 Sequence Variants: Comparison With Other Vitamin D-mediated Hypercalcemia Disorders.

Authors:  Sarah M Azer; Lisa E Vaughan; Peter J Tebben; David J Sas
Journal:  J Endocr Soc       Date:  2021-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.